These results reveal that physiological levels of circulating hPRL in the NSG-Pro mouse can support the growth of latent distant metastases of an ER+ breast cancer model and provide the first preclinical evidence of efficacy of PRL pathway targeting against disseminated disease. The gene discussed is ESR1; the disease is breast cancer.